Distinctive Expression Patterns of Glycoprotein Non-metastatic B and Folliculin in Renal Tumors in Patients with Birt-Hogg-Dubé Syndrome

Overview

Journal Cancer Sci

Specialty Oncology

Date 2015 Jan 17

PMID 25594584

Citations 17

Authors

Mitsuko Furuya

Seung-Beom Hong

Reiko Tanaka

Naoto Kuroda

Yoji Nagashima

Kiyotaka Nagahama

Takahito Suyama

Masahiro Yao

Yukio Nakatani

Affiliations

Soon will be listed here.

Abstract

Birt-Hogg-Dubé syndrome (BHD) is an inherited disorder associated with a germline mutation of the folliculin gene (FLCN). The affected families have a high risk for developing multiple renal cell carcinomas (RCC). Diagnostic markers that distinguish between FLCN-related RCC and sporadic RCC have not been investigated, and many patients with undiagnosed BHD fail to receive proper medical care. We investigated the histopathology of 27 RCCs obtained from 18 BHD patients who were diagnosed by genetic testing. Possible somatic mutations of RCC lesions were investigated by DNA sequencing. Western blotting and immunohistochemical staining were used to compare the expression levels of FLCN and glycoprotein non-metastatic B (GPNMB) between FLCN-related RCCs and sporadic renal tumors (n = 62). The expression of GPNMB was also evaluated by quantitative RT-PCR. Histopathological analysis revealed that the most frequent histological type was chromophobe RCC (n = 12), followed by hybrid oncocytic/chromophobe tumor (n = 6). Somatic mutation analysis revealed small intragenic mutations in six cases and loss of heterozygosity in two cases. Western blot and immunostaining analyses revealed that FLCN-related RCCs showed overexpression of GPNMB and underexpression of FLCN, whereas sporadic tumors showed inverted patterns. GPNMB mRNA in FLCN-related RCCs was 23-fold more abundant than in sporadic tumors. The distinctive expression patterns of GPNMB and FLCN might identify patients with RCCs who need further work-up for BHD.

Citing Articles

PRDM10 RCC: A Birt-Hogg-Dubé-like Syndrome Associated With Lipoma and Highly Penetrant, Aggressive Renal Tumors Morphologically Resembling Type 2 Papillary Renal Cell Carcinoma.

Schmidt L, Vocke C, Ricketts C, Blake Z, Choo K, Nielsen D Urology. 2023; 179:58-70.

PMID: 37331486 PMC: 10592549. DOI: 10.1016/j.urology.2023.04.035.

TFEB and TFE3 drive kidney cystogenesis and tumorigenesis.

Di Malta C, Zampelli A, Granieri L, Vilardo C, De Cegli R, Cinque L EMBO Mol Med. 2023; 15(5):e16877.

PMID: 36987696 PMC: 10165358. DOI: 10.15252/emmm.202216877.

Germline- and Somatic-Inactivating FLCN Variants in Parathyroid Cancer and Atypical Parathyroid Tumors.

Jha S, Welch J, Tora R, Lack J, Warner A, Del Rivero J J Clin Endocrinol Metab. 2023; 108(10):2686-2698.

PMID: 36935552 PMC: 10505536. DOI: 10.1210/clinem/dgad136.

GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.

Salles D, Asrani K, Woo J, Vidotto T, Liu H, Vidal I J Pathol. 2022; 257(2):158-171.

PMID: 35072947 PMC: 9310781. DOI: 10.1002/path.5875.

A systematic review assessing the existence of pneumothorax-only variants of FLCN. Implications for lifelong surveillance of renal tumours.

Matsumoto K, Lim D, Pharoah P, Maher E, Marciniak S Eur J Hum Genet. 2021; 29(11):1595-1600.

PMID: 34267338 PMC: 8560836. DOI: 10.1038/s41431-021-00921-x.

References

Safadi F, Xu J, Smock S, Rico M, Owen T, Popoff S . Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts. J Cell Biochem. 2001; 84(1):12-26. DOI: 10.1002/jcb.1259. View

Kuroda N, Furuya M, Nagashima Y, Gotohda H, Moritani S, Kawakami F . Intratumoral peripheral small papillary tufts: a diagnostic clue of renal tumors associated with Birt-Hogg-Dubé syndrome. Ann Diagn Pathol. 2014; 18(3):171-6. DOI: 10.1016/j.anndiagpath.2014.03.002. View

Nickerson M, Warren M, Toro J, Matrosova V, Glenn G, Turner M . Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell. 2002; 2(2):157-64. DOI: 10.1016/s1535-6108(02)00104-6. View

Pavlovich C, Walther M, Eyler R, Hewitt S, Zbar B, Linehan W . Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol. 2002; 26(12):1542-52. DOI: 10.1097/00000478-200212000-00002. View

Khoo S, Kahnoski K, Sugimura J, Petillo D, Chen J, Shockley K . Inactivation of BHD in sporadic renal tumors. Cancer Res. 2003; 63(15):4583-7. View

Warren M, Torres-Cabala C, Turner M, Merino M, Matrosova V, Nickerson M . Expression of Birt-Hogg-Dubé gene mRNA in normal and neoplastic human tissues. Mod Pathol. 2004; 17(8):998-1011. DOI: 10.1038/modpathol.3800152. View

Vocke C, Yang Y, Pavlovich C, Schmidt L, Nickerson M, Torres-Cabala C . High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst. 2005; 97(12):931-5. DOI: 10.1093/jnci/dji154. View

Ogawa T, Nikawa T, Furochi H, Kosyoji M, Hirasaka K, Suzue N . Osteoactivin upregulates expression of MMP-3 and MMP-9 in fibroblasts infiltrated into denervated skeletal muscle in mice. Am J Physiol Cell Physiol. 2005; 289(3):C697-707. DOI: 10.1152/ajpcell.00565.2004. View

Baba M, Hong S, Sharma N, Warren M, Nickerson M, Iwamatsu A . Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A. 2006; 103(42):15552-7. PMC: 1592464. DOI: 10.1073/pnas.0603781103. View

10.

Adley B, Smith N, Nayar R, Yang X . Birt-Hogg-Dubé syndrome: clinicopathologic findings and genetic alterations. Arch Pathol Lab Med. 2006; 130(12):1865-70. DOI: 10.5858/2006-130-1865-BSCFAG. View

11.

Gad S, Lefevre S, Khoo S, Giraud S, Vieillefond A, Vasiliu V . Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer. 2006; 96(2):336-40. PMC: 2360004. DOI: 10.1038/sj.bjc.6603492. View

12.

Toro J, Wei M, Glenn G, Weinreich M, Toure O, Vocke C . BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet. 2008; 45(6):321-31. PMC: 2564862. DOI: 10.1136/jmg.2007.054304. View

13.

Delongchamps N, Galmiche L, Eiss D, Rouach Y, Vogt B, Timsit M . Hybrid tumour 'oncocytoma-chromophobe renal cell carcinoma' of the kidney: a report of seven sporadic cases. BJU Int. 2009; 103(10):1381-4. DOI: 10.1111/j.1464-410X.2008.08263.x. View

14.

Tomihari M, Hwang S, Chung J, Cruz Jr P, Ariizumi K . Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD-dependent fashion. Exp Dermatol. 2009; 18(7):586-95. PMC: 2774115. DOI: 10.1111/j.1600-0625.2008.00830.x. View

15.

Hasumi Y, Baba M, Ajima R, Hasumi H, Valera V, Klein M . Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci U S A. 2009; 106(44):18722-7. PMC: 2765925. DOI: 10.1073/pnas.0908853106. View

16.

Menko F, van Steensel M, Giraud S, Friis-Hansen L, Richard S, Ungari S . Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol. 2009; 10(12):1199-206. DOI: 10.1016/S1470-2045(09)70188-3. View

17.

Pahl M, Vaziri N, Yuan J, Adler S . Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease. Clin J Am Soc Nephrol. 2009; 5(1):56-61. PMC: 2801651. DOI: 10.2215/CJN.03390509. View

18.

Petersson F, Gatalica Z, Grossmann P, Perez Montiel M, Alvarado Cabrero I, Bulimbasic S . Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. Virchows Arch. 2010; 456(4):355-65. DOI: 10.1007/s00428-010-0898-4. View

19.

Hong S, Oh H, Valera V, Baba M, Schmidt L, Linehan W . Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization. PLoS One. 2011; 5(12):e15793. PMC: 3012117. DOI: 10.1371/journal.pone.0015793. View

20.

Cash T, Gruber J, Hartman T, Henske E, Simon M . Loss of the Birt-Hogg-Dubé tumor suppressor results in apoptotic resistance due to aberrant TGFβ-mediated transcription. Oncogene. 2011; 30(22):2534-46. PMC: 3109270. DOI: 10.1038/onc.2010.628. View